← Eichor
Study identifier: NCT06940232 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Validating a Blood Test for the Detection of Traumatic Brain Injury in Children

Condition: Pediatric Traumatic Brain Injury  ·  Sponsor: University of Nebraska

PhaseN/A
Planned participants330
Who can joinAll sexes, N/A to 17 Years
Healthy volunteersNo

About this study

The primary objective of this study is to establish if Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase L1 (UCH-L1) are predictive of computed tomography (CT) findings in pediatric traumatic brain injuries (TBI). The participant population is pediatric patients, ages 0 to less than 18 years old with a possible TBI or trauma-related injury who have blood drawn per standard of care in the emergency department. Blood samples will be analyzed using the i-STAT TBI cartridge (Abbott Laboratories, Abbott Park, IL, USA) by the Emergency Department charge nurse within one hour of collection of the blood sample. Clinical outcomes will be assessed via telephone interview with a parent at 3 and 6 months for all surviving TBI patients.

This description comes directly from the study's public registry record.

Talk to the study team

Megan McChesney, BSN, RN, CPN  ·  531-375-3835  ·  mmcchesney@unmc.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Children's NebraskaOmaha, Nebraska, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06940232